TG Therapeutics Inc [TGTX] stock prices are up 1.29% to $15.69 at the moment. An important factor to consider is whether the stock is rising or falling in short-term value. The TGTX shares have gain 4.25% over the last week, with a monthly amount glided 17.79%, and seem to be holding up well over a long-time horizon.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
On 8, March 2024, TG Therapeutics Announces Schedule of Data Presentations for BRIUMVI® (ublituximab) in Multiple Sclerosis at the American Academy of Neurology 2024 Annual Meeting. In a post published today on Yahoo Finance, TG Therapeutics, Inc. (NASDAQ: TGTX), today announced the schedule of data presentations highlighting data from the ULTIMATE I & II Phase 3 trials evaluating BRIUMVI® (ublituximab-xiiy) in patients with relapsing forms of multiple sclerosis (RMS), at the upcoming American Academy of Neurology 2024 annual meeting, being held April 13 – 18, 2024, in Dever, Colorado. Abstracts are now available online and can be accessed on the AAN meeting website at https://www.aan.com/msa/Public/Events/Index/49. Details of the upcoming presentations are outlined below.
From an analyst’s perspective:
TG Therapeutics Inc [NASDAQ: TGTX] stock has seen the most recent analyst activity on August 02, 2023, when Goldman upgraded its rating to a Neutral and also revised its price target to $12 from $16. On May 20, 2022, BofA Securities initiated with a Underperform rating and assigned a price target of $5 on the stock. B. Riley Securities reiterated its Buy rating and decreased its price target to $35 on February 23, 2022. Goldman downgraded its rating to a Sell and reduced its price target to $26 on November 15, 2021. Goldman started tracking with a Neutral rating for this stock on April 20, 2021, and assigned it a price target of $50. In a note dated April 19, 2021, H.C. Wainwright reiterated an Buy rating on this stock and boosted its target price from $79 to $89.
The stock price of TG Therapeutics Inc [TGTX] has been fluctuating between $6.46 and $35.67 over the past year. Currently, Wall Street analysts expect the stock to reach $18.4 within the next 12 months. TG Therapeutics Inc [NASDAQ: TGTX] shares were valued at $15.69 at the most recent close of the market. An investor can expect a potential return of 17.27% based on the average TGTX price forecast.
Analyzing the TGTX fundamentals
The TG Therapeutics Inc [NASDAQ:TGTX] reported sales of 233.66M for trailing twelve months, representing a surge of 54863.75%. Gross Profit Margin for this corporation currently stands at 0.94% with Operating Profit Margin at 0.09%, Pretax Profit Margin comes in at 0.06%, and Net Profit Margin reading is 0.06%. To continue investigating profitability, this company’s Return on Assets is posted at 0.04, Equity is -0.01 and Total Capital is 0.07. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of0.63.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 15.45 points at the first support level, and at 15.22 for the second support level. However, for the 1st resistance point, the stock is sitting at 15.87, and for the 2nd resistance point, it is at 16.06.
TG Therapeutics Inc [TGTX] reported earnings per share of -$0.1 for its fiscal quarter that ended on 12/30/2023. Based on the Wall Street analysts’ estimates, the company was expected to report earnings of -$0.1/share, meaning a difference of $0 and a surprise factor of 0.00%. By comparison, the stated earnings for the previous quarter ended on 9/29/2023 were $0.73 per share as compared to estimates of $0.12 per share, a difference of $0.61 representing a surprise of 508.30%.
Ratios To Look Out For
It’s worth pointing out that TG Therapeutics Inc [NASDAQ:TGTX]’s Current Ratio is 5.92. On the other hand, the Quick Ratio is 5.18, and the Cash Ratio is 1.73. Considering the valuation of this stock, the price to sales ratio is 10.37, the price to book ratio is 14.80 and price to earnings (TTM) ratio is 1112.77.
Transactions by insiders
Recent insider trading involved Lonial Sagar, Director, that happened on Mar 13 ’24 when 5000.0 shares were sold. Director, Charney Laurence N completed a deal on Mar 12 ’24 to sell 22000.0 shares. Meanwhile, Director Charney Laurence N sold 17500.0 shares on Jan 05 ’24.
